Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Im, Seock-Ah, Xu, Binghe, Li, Wei, Robson, Mark, Ouyang, Quchang, Yeh, Dah-Cherng, Iwata, Hiroji, Park, Yeon Hee, Sohn, Joo Hyuk, Tseng, Ling-Ming, Goessl, Carsten, Wu, Wenting, Masuda, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260217/
https://www.ncbi.nlm.nih.gov/pubmed/32472001
http://dx.doi.org/10.1038/s41598-020-63033-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260217/
https://www.ncbi.nlm.nih.gov/pubmed/32472001
http://dx.doi.org/10.1038/s41598-020-63033-4

Ejemplares similares